» Articles » PMID: 24511087

Evidence-based Focused Review of the Status of Hematopoietic Stem Cell Transplantation As Treatment of Sickle Cell Disease and Thalassemia

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 2014 Feb 11
PMID 24511087
Citations 22
Authors
Affiliations
Soon will be listed here.
Citing Articles

Communicating Prognosis in Sickle Cell Disease: A Qualitative Study of Adolescents with Sickle Cell Disease, Their Parents and Providers.

Pecker L, Roth M, Landman S, Cunningham L, Silver E, Manwani D Ann Pediatr Child Health. 2024; 3(1).

PMID: 39712473 PMC: 11661846.


Chronic automated red cell exchange therapy for sickle cell disease.

Zakieh A, Mercure-Corriveau N, Lanzkron S, Feng X, Vozniak S, Crowe E Transfusion. 2024; 64(8):1509-1519.

PMID: 39003570 PMC: 11316647. DOI: 10.1111/trf.17924.


Organ function indications and potential improvements following curative therapy for sickle cell disease.

Hulbert M, King A, Shenoy S Hematology Am Soc Hematol Educ Program. 2022; 2022(1):277-282.

PMID: 36485131 PMC: 9820741. DOI: 10.1182/hematology.2022000372.


How to Facilitate Decision-Making for Hematopoietic Stem Cell Transplantation in Patients With Hemoglobinopathies. The Perspectives of Healthcare Professionals.

Mekelenkamp H, van Zanten H, de Vries M, Lankester A, Smiers F Front Pediatr. 2021; 9:690309.

PMID: 34485192 PMC: 8416427. DOI: 10.3389/fped.2021.690309.


Supramolecular nanosubstrate-mediated delivery system enables CRISPR-Cas9 knockin of hemoglobin beta gene for hemoglobinopathies.

Yang P, Chou S, Li J, Hui W, Liu W, Sun N Sci Adv. 2020; 6(43).

PMID: 33097539 PMC: 7608838. DOI: 10.1126/sciadv.abb7107.